Arcede Pharma is a pharmaceutical company. The company conducts research and development in the field of chronic obstructive pulmonary disease, also abbreviated as COPD, and severe asthma. The company's product portfolio includes medicines intended for the treatment and relief of the above ailments. The largest activity is found within the Nordic market. The company was created via a spin-off of Respiratorius in 2022 and today has its headquarters in Lund.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Lessly Sommer | 8,56 | 8,56 | 2023-09-27 |
| Bengt Anders Ingemar Axelsson | 7,02 | 7,02 | 2023-09-27 |
| Nordnet Pensionsförsäkring | 5,66 | 5,66 | 2023-09-27 |
| Christer Fåhraeus | 5,06 | 5,06 | 2023-09-27 |
| Anders Haskel | 3,91 | 3,91 | 2023-09-27 |
| Avanza Pension | 3,56 | 3,56 | 2023-09-27 |
| Anders Franzén | 2,42 | 2,42 | 2023-09-27 |
| Arian Ismail | 2,31 | 2,31 | 2023-09-27 |
| Leif Nykvist | 1,74 | 1,74 | 2023-09-27 |
| Valcuria Holding AB | 1,74 | 1,74 | 2023-09-27 |
2024-02-12 Bokslutskommuniké 2023